Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PEC-PRO: A new prognostic score from a series of 87 patients with localized perivascular epithelioid cell neoplasms (PEComas) treated with curative intent.
Gantzer J, Toulmonde M, Severac F, Chamseddine AN, Charon-Barra C, Vinson C, Hervieu A, Bourgmayer A, Bertucci F, Ryckewaert T, Valentin T, Firmin N, Chaigneau L, Bompas E, Follana P, Rioux-Leclercq N, Soibinet-Oudot P, Bozec L, Le Loarer F, Weingertner N, Chevreau C, Duffaud F, Blay JY, Kurtz JE, Schöffski P, Brahmi M, Malouf GG. Gantzer J, et al. Among authors: toulmonde m. Cancer. 2024 Mar 12. doi: 10.1002/cncr.35277. Online ahead of print. Cancer. 2024. PMID: 38470379
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with oncolytic viral therapy: a phase 2 trial of intratumoral JX-594 combined with avelumab and low-dose cyclophosphamide.
Toulmonde M, Guegan JP, Spalato-Ceruso M, Peyraud F, Kind M, Vanhersecke L, Le Loarer F, Perret R, Cantarel C, Bellera C, Bessede A, Italiano A. Toulmonde M, et al. Mol Cancer. 2024 Feb 20;23(1):38. doi: 10.1186/s12943-024-01946-8. Mol Cancer. 2024. PMID: 38378555 Free PMC article. Clinical Trial.
Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study.
Sun CM, Toulmonde M, Spalato-Ceruso M, Peyraud F, Bessede A, Kind M, Cousin S, Buy X, Palussiere J, Bougouin A, Sautès-Fridman C, Fridman HW, Pulido M, Italiano A. Sun CM, et al. Among authors: toulmonde m. Mol Cancer. 2024 Feb 19;23(1):37. doi: 10.1186/s12943-024-01942-y. Mol Cancer. 2024. PMID: 38374062 Free PMC article.
Handling missing covariates in observational studies: an illustration with the assessment of prognostic factors of survival outcomes in soft-tissue or visceral sarcomas in irradiated fields (SIF).
Huchet N, Penel N, Bonvalot S, Thariat J, Ducimetière F, Giraud A, Toulmonde M, Le Cesne A, Blay JY, Bellera C. Huchet N, et al. Among authors: toulmonde m. Ther Adv Med Oncol. 2024 Jan 19;16:17588359231220999. doi: 10.1177/17588359231220999. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38249328 Free PMC article.
Improved nationwide survival of sarcoma patients with a network of reference centers.
Blay JY, Penel N, Valentin T, Anract P, Duffaud F, Dufresne A, Verret B, Cordoba A, Italiano A, Brahmi M, Henon C, Amouyel T, Ray-Coquard I, Ferron G, Boudou-Rouquette P, Tlemsani C, Salas S, Rochwerger R, Faron M, Bompas E, Ducassou A, Gangloff D, Gouin F, Firmin N, Piperno-Neumann S, Rios M, Ropars M, Kurtz JE, Le Nail LR, Bertucci F, Carrere S, Llacer C, Watson S, Bonvalot S, Leroux A, Perrin C, Gantzer J, Pracht M, Narciso B, Monneur A, Lebbe C, Hervieu A, Saada-Bouzid E, Dubray-Longeras P, Fiorenza F, Chaigneau L, Nevieres ZM, Soibinet P, Bouché O, Guillemet C, Spano JP, Ruzic JC, Isambert N, Vaz G, Meeus P, Karanian M, Ngo C, Coindre JM, De Pinieux G, Le Loarer F, Ducimetiere F, Chemin C, Morelle M, Toulmonde M, Le Cesne A. Blay JY, et al. Among authors: toulmonde m. Ann Oncol. 2024 Apr;35(4):351-363. doi: 10.1016/j.annonc.2024.01.001. Epub 2024 Jan 20. Ann Oncol. 2024. PMID: 38246351 Free article.
Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): Presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years.
Blay JY, Tlemsani C, Toulmonde M, Italiano A, Rios M, Bompas E, Valentin T, Duffaud F, Le Nail LR, Watson S, Firmin N, Dubray-Longeras P, Ropars M, Perrin C, Hervieu A, Lebbe C, Saada-Bouzid E, Soibinet P, Fiorenza F, Bertucci F, Boudou P, Vaz G, Bonvalot S, Honoré C, Marec-Berard P, Minard V, Cleirec M, Biau D, Meeus P, Babinet A, Dumaine V, Carriere S, Fau M, Decanter G, Gouin F, Ngo C, Le Loarer F, Karanian M, Meurgey A, Dufresne A, Brahmi M, Chemin-Airiau C, Ducimetiere F, Penel N, Le Cesne A; NETSARC/REPPS/RESOS and French Sarcoma Group- Groupe d′Etude des Tumeurs Osseuses (GSF-GETO) networks. Blay JY, et al. Among authors: toulmonde m. Eur J Cancer. 2024 Jan;196:113454. doi: 10.1016/j.ejca.2023.113454. Epub 2023 Nov 23. Eur J Cancer. 2024. PMID: 38008029 Free article.
Evolution of Patterns of Care and Outcomes in the Real-Life Setting for Patients with Metastatic GIST Treated in Three French Expert Centers over Three Decades.
Toulmonde M, Dinart D, Brahmi M, Verret B, Jean-Denis M, Ducimetière F, Desolneux G, Méeus P, Palussière J, Buy X, Bouhamama A, Gillon P, Dufresne A, Hénon C, Le Loarer F, Karanian M, Ngo C, Mathoulin-Pélissier S, Bellera C, Le Cesne A, Blay JY, Italiano A. Toulmonde M, et al. Cancers (Basel). 2023 Aug 28;15(17):4306. doi: 10.3390/cancers15174306. Cancers (Basel). 2023. PMID: 37686582 Free PMC article.
Impact of the coronavirus disease 2019 pandemic on sarcoma management in France: a 2019 and 2020 comparison.
Penel N, Cantarel C, Chemin-Airiau C, Ducimetiere F, Gouin F, Le Loarer F, Toulmonde M, Piperno-Neumann S, Bellera C, Honore C, Blay JY, Mathoulin-Pelissier S. Penel N, et al. Among authors: toulmonde m. Ther Adv Med Oncol. 2023 Aug 31;15:17588359231192400. doi: 10.1177/17588359231192400. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37661954 Free PMC article.
Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years.
Blay JY, Piperno-Neumann S, Watson S, Dufresne A, Valentin T, Duffaud F, Toulmonde M, Italiano A, Bertucci F, Tlemsani C, Firmin N, Bompas E, Perrin C, Ropars M, Saada-Bouzid E, Dubray-Longeras P, Hervieu A, Lebbe C, Gantzer J, Chaigneau L, Fiorenza F, Rios M, Isambert N, Soibinet P, Boudou-Roquette P, Verret B, Ferron G, Ryckewaert T, Lebellec L, Brahmi M, Gouin F, Meeus P, Vaz G, Le Loarer F, Karanian M, De Pinieux G, Ducimetiere F, Chemin C, Morelle M, Le Cesne A, Penel N; NETSARC/REPPS/RESOS and French Sarcoma Group–Groupe d′Etude des Tumeurs Osseuses (GSF-GETO) networks. Blay JY, et al. Among authors: toulmonde m. Eur J Cancer. 2023 Oct;192:113262. doi: 10.1016/j.ejca.2023.113262. Epub 2023 Jul 29. Eur J Cancer. 2023. PMID: 37625241 Free article.
Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort.
Trédan O, Toulmonde M, Le Tourneau C, Montane L, Italiano A, Ray-Coquard I, De La Fouchardière C, Bertucci F, Gonçalves A, Gomez-Roca C, You B, Attignon V, Boyault S, Cassier PA, Dufresne A, Tabone-Eglinger S, Viari A, Sohier E, Kamal M, Garin G, Blay JY, Pérol D. Trédan O, et al. Among authors: toulmonde m. Cancers (Basel). 2023 Jun 30;15(13):3441. doi: 10.3390/cancers15133441. Cancers (Basel). 2023. PMID: 37444551 Free PMC article.
105 results